NASDAQ · Biotechnology

Fusion Pharmaceuticals Inc. (FUSN) Stock

$21.55 +0.14% NASDAQ: FUSN Healthcare

Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies.

Valuation

MetricValue
Price$21.55
Market Cap$1.83B
P/E Ratio-14.86
P/B Ratio6.36
P/S Ratio886.38
EPS (TTM)$-1.45
52-Week High$21.60
52-Week Low$2.31
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.34%
ROA-33.20%
ROCE-36.80%
Gross Margin34.96%
Operating Margin-4950.00%
Net Margin-4750.00%
Debt/Equity0.23
Current Ratio15.01

Annual Financials (USD)

Metric20192020202120222023
Revenue$0$0$1.0M$1.0M$2.0M
Operating Profit$-18.0M$-38.0M$-82.0M$-88.0M$-99.0M
Net Profit$-16.0M$-78.0M$-81.0M$-88.0M$-95.0M
EPS$-0.10$-3.56$-1.90$-2.00$-1.45
Op Margin——-5695.5%-6025.6%-4798.4%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$69.0M$311.0M$252.0M$219.0M$286.0M
Total Liabilities$103.0M$16.0M$21.0M$57.0M$63.0M
Cash$65.0M$91.0M$53.0M$44.0M$62.0M
Borrowings$6.0M$0$7.0M$40.0M$50.0M

Latest News

Should You Buy Coca-Cola Stock Before July 28? Motley Fool · Jul 16, 2026 SpaceX Just Fell Below Its IPO Price. Here's What Happens Next, According to History. Motley Fool · Jul 16, 2026 Solana trading volume for one stock beats its Nasdaq session TheStreet · Jul 16, 2026 What This Credo Insider's $12.6 Million Sale Means With Shares Up 121% Motley Fool · Jul 16, 2026 Market Chatter: Boeing, Airbus Vie for Potential SMBC Narrowbody Jet Order MT Newswires · Jul 16, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-14.0M$-30.0M$-76.0M$-73.0M$-82.0M
Investing Cash Flow$-1.0M$-212.0M$36.0M$21.0M$-47.0M
Financing Cash Flow$52.0M$193.0M$0$42.0M$142.0M
Net Cash Flow$38.0M$25.0M$-38.0M$-9.0M$18.0M
Free Cash Flow$-14.0M$-31.0M$-77.0M$-75.0M$-86.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.42
EV / EBITDA-20.79
FCF Yield-4.67%
Quick Ratio15.01
Interest Coverage-19.21
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMAMAmbrx Biopharma Inc. $28.00 +0.07% -13.86 $1.77B 0.00%
ASTH $36.33 -0.51% 63.95 $1.80B 0.00%
BLUBELLUS Health Inc. $14.75 +0.03% -22.34 $1.87B 0.00%
CALTCalliditas Therapeutics AB (publ) $40.00 -0.10% -22.08 $2.15B 0.00%
CINCCinCor Pharma, Inc. $29.06 +0.00% -20.46 $1.27B 0.00%

About Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology. This innovative system enables the attachment of alpha particle-emitting isotopes to diverse targeting molecules, facilitating the targeted delivery of these potent payloads directly to cancerous growths. Its leading investigational compound, FPI-1434, is currently progressing through Phase 1 clinical trials as a singular treatment for individuals suffering from solid tumors that express the insulin-like growth factor 1 receptor. Beyond this, Fusion is conducting preclinical research into FPI-1434's effectiveness in conjunction with existing checkpoint inhibitors and DNA damage response inhibitors. These studies aim to thoroughly evaluate its anti-tumor effects, ideal dosage regimens, and pharmacological interactions within combination therapies. Furthermore, the firm is moving its earlier-stage candidate, FPI-1966, into clinical evaluation for the management of head and neck, and bladder cancers exhibiting fibroblast growth factor receptor. Fusion Pharmaceuticals also maintains a strategic partnership with AstraZeneca UK Limited, collaborating on the identification, advancement, and market introduction of alpha-emitting radiopharmaceuticals and combined cancer treatments. The company, established in 2014, is headquartered in Hamilton, Canada.

Fusion Pharmaceuticals Inc. is headquartered in CA.

Fusion Pharmaceuticals Inc. (FUSN) stock trades at $21.55 with a market capitalization of $1.83B. The stock is valued at a price-to-earnings (P/E) ratio of -14.86, price-to-book of 6.36, price-to-sales of 886.38. Over the past 52 weeks the stock has ranged between $2.31 and $21.60, and currently trades at its 52-week high.

On profitability, Fusion Pharmaceuticals Inc. generates a return on equity (ROE) of -49.34%, return on capital employed of -36.80%, an operating margin of -4950.00%, a net profit margin of -4750.00%.

Official website: fusionpharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides